VERAXA Biotech (NASDAQ: VRXA), a developer of next-generation antibody-based cancer therapies, announced the appointment of Raju Willener as chief financial officer, effective immediately. Willener brings more than three decades of international financial leadership experience, spanning global capital markets, investment banking, corporate finance, asset management, and strategic leadership. He will report to CEO and Co-Founder Christoph Antz, Ph.D., and is expected to support the company's capital strategy, strategic opportunities, and continued development of its proprietary BiTAC(R) technology platform and oncology pipeline.
Prior to joining VERAXA, Willener served as director of corporate development at Exentis Group AG before being appointed CFO in 2025, where he led M&A initiatives, financial strategy, and key corporate functions. Earlier in his career, he held senior executive and investment positions overseeing areas including corporate finance, capital markets, investor relations, and investment portfolios exceeding CHF 30 billion in assets under management.
This appointment comes as VERAXA focuses on advancing its pipeline of bispecific T cell engagers, bispecific ADCs, and other innovative antibody formats. The company's proprietary BiTAC(R) technology is designed to harness the immune system to target and eliminate cancer cells, with potential applications across multiple oncology indications. With Willener's extensive financial background, the company is well-positioned to navigate the complexities of drug development and commercialization, potentially accelerating the path to market for its therapies.
Willener's experience in capital markets and asset management will be invaluable as VERAXA seeks to secure funding for its research and development efforts. The company's ability to attract a CFO with such a strong track record underscores its commitment to building a world-class leadership team. Investors and industry watchers will be keen to see how Willener's strategic guidance influences VERAXA's next phases of growth, including potential partnerships and clinical trial advancements.
For more information, visit the full press release at https://nnw.fm/jcHOU. The latest news and updates relating to VRXA are available in the company's newsroom at https://ibn.fm/VRXA.
Forward-looking statements in this article involve risks and uncertainties, as detailed in the company's filings with the SEC. Undue reliance should not be placed on these statements, which are based on information available on the date hereof.
